Epstein Secrets

the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics) PSA, FREE 0.33 Not Estab. ng/mL I 0.31 10/27/201S BioReference Laboratories, Inc. Elmwood Park, NJ 07407 James Weisberger M.D. Page 3 of S Laboratory Director Prin

s 6 126 7 154 8 183 9 212 10 240 11 269 12 298 *recommended ranges-American Diabetes Association(2010) I Previous Result] Date NOTE: Hemolysis, rare hemoglobin variants and thalassemia major may affect glycemic results. DIHYDROTESTOSTERONE TO FOLLOW SEE REPORT 153.0 10/27/2015 BioRefer

th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). Not Estab. ng/mL to moderate or marked of the obtained used I 0.33 ¶01/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate

->6.5 Consistent Alt(S) eAG(ESTIFIATED AV 6 126 7 154 8 183 9 212 10 240 11 269 12 298 'recomended ranges-American Diabetes NOTE: Hemolysis, rare hemoglobin variants and thalas NJ GROWT-i gil.#. ,:::::: . ..:;:i3Zikiii.Riniar:::..itietnveii44: <5.7 % 6.0 Hf 1/27/2016 -diabetic) r

th different assay methods or kits cannot be interchangeably. ASSAY INFORMATION: Method Electrocheedluninescence Immunoassay (Roche Diagnostics). Not Estab. ng/mi. to moderate or marked of the obtained used 1 0.33 101/27/2016 % FREE PSA TNP FREE PSA RISK ASSESSMENT The probability of prostate

.>6.5 Consistent AIC(X) eAG(ESTIMATED AVERAGE 6 126 7 154 8 183 9 212 10 240 11 269 12 298 *recommended ranges-American Diabetes Hemolysis, rare hemoglobin variants and thalassemia NO GROWTH W.r.4,11:::::=ViiiiirLaarigaTZ2=C7.31, illiat,W4 24: <5.7 6.0 HI lin/27/2016 -diabetic) ri